Skip to main content
SpringerLink
Log in

Liver Involvement in Rheumatic Diseases

  • Chapter
  • First Online:
Book cover Gastrointestinal and Hepatic Manifestations of Rheumatic Diseases

Abstract

Liver dysfunction may be caused by various factors such as viruses, disease treatments, alcohol use, and metabolic or autoimmune diseases. The associations between rheumatic diseases and the liver are complex, because rheumatic diseases target multiple systemic organs, including the liver. In addition, both treatment with immunosuppressants and secondary viral infections can cause liver dysfunction. Although liver dysfunction in rheumatic diseases is usually mild, liver failure has been reported in some cases. Therefore, understanding the characteristics of liver failure that may occur with different rheumatic diseases is essential for the treatment of these diseases. Clinicians must consider and treat liver dysfunction in patients with a rheumatic disease with both disorders in mind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kojima H, Uemura M, Sakurai S, et al. Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol. 2002;37:617–25.

    Article  PubMed  Google Scholar 

  2. Zheng RH, Wang JH, Wang SB, et al. Clinical and immunopathological features of patients with lupus hepatitis. Chin Med J (Engl). 2013;126:260–6.

    CAS  Google Scholar 

  3. Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med. 1980;69:187–94.

    Article  CAS  PubMed  Google Scholar 

  4. Miller MH, Urowitz MB, Gladman DD, Blendis LM. The liver in systemic lupus erythematosus. Q J Med. 1984;53:401–9.

    CAS  PubMed  Google Scholar 

  5. Luangjaru S, Kullavanijaya P. Gastrointestinal and hepatobiliary manifestations in systemic lupus erythematosus. J Med Assoc Thail. 2005;88:71–5.

    Google Scholar 

  6. Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol. 2008;35:2159–64.

    Article  CAS  PubMed  Google Scholar 

  7. Piga M, Vacca A, Porru G, Cauli A, Mathieu A. Liver involvement in systemic lupus erythematosus: incidence, clinical course and outcome of lupus hepatitis. Clin Exp Rheumatol. 2010;28:504–10.

    CAS  PubMed  Google Scholar 

  8. Her M, Lee Y, Jung E, Kim T, Kim D. Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis. Rheumatol Int. 2011;31:79–84. https://doi.org/10.1007/s00296-009-1237-4.

    Article  CAS  PubMed  Google Scholar 

  9. Huang D, Aghdassi E, Su J, Mosko J, et al. Prevalence and risk factors for liver biochemical abnormalities in Canadian patients with systemic lupus erythematosus. J Rheumatol. 2012;39:254–61. https://doi.org/10.3899/jrheum.110310.

    Article  PubMed  Google Scholar 

  10. Takahashi A, Abe K, Saito R, et al. Liver dysfunction in patients with systemic lupus erythematosus. Intern Med. 2013;52:1461–5.

    Article  PubMed  Google Scholar 

  11. Takahashi A, Abe K, Yokokawa J, et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 2010;40:1092–7.

    Article  PubMed  Google Scholar 

  12. Fernandes L, Sullivan S, McFarlane IG, et al. Studies on the frequency and pathogenesis of liver involvement in rheumatoid arthritis. Ann Rheum Dis. 1979;38:501–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Spooner RJ, Smith DH, Bedford D, Beck PR. Serum gamma-glutamyltransferase and alkaline phosphatase in rheumatoid arthritis. J Clin Pathol. 1982;35:638–41.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Lowe JR, Pickup ME, Dixon JS, et al. Gamma glutamyl transpeptidase levels in arthritis: a correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1978;37:428–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Akesson A, Berglund K, Karlsson M. Liver function in some common rheumatic disorders. Scand J Rheumatol. 1980;9:81–8.

    Article  CAS  PubMed  Google Scholar 

  16. Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren’s syndrome. Br J Rheumatol. 1994;33:745–8.

    Article  CAS  PubMed  Google Scholar 

  17. Lindgren S, Manthorpe R, Eriksson S. Autoimmune liver disease in patients with primary Sjögren’s syndrome. J Hepatol. 1994;20:354–8.

    Article  CAS  PubMed  Google Scholar 

  18. Montaño-Loza AJ, Crispín-Acuña JC, Remes-Troche JM, Uribe M. Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren’s syndrome. Ann Hepatol. 2007;6:150–5.

    PubMed  Google Scholar 

  19. Chen J. Liver, gall and pancreas. In: Liu TH, Liu TH, Li WH, editors. Diagnostic pathology. Beijing: People Health Press; 1995. p. 242.

    Google Scholar 

  20. Ebert EC, Hagspiel KD, Nagar M, Schlesinger N. Gastrointestinal involvement in polyarteritis nodosa. Clin Gastroenterol Hepatol. 2008;6(9):960–6.

    Article  PubMed  Google Scholar 

  21. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine. 1991;70:118–36.

    Article  CAS  PubMed  Google Scholar 

  22. Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine. 2002;81:194–200.

    Article  PubMed  Google Scholar 

  23. Pay S, Türkçapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–44.

    Article  PubMed  Google Scholar 

  24. Cagatay Y, Gul A, Cagatay A, et al. Adult-onset Still’s disease. Int J Clin Pract. 2009;63:1050–5.

    Article  CAS  PubMed  Google Scholar 

  25. Zhu G, Liu G, Liu Y, Xie Q, Shi G. Liver abnormalities in adult onset Still’s disease: a retrospective study of 77 Chinese patients. J Clin Rheumatol. 2009;15:284–8.

    Article  PubMed  Google Scholar 

  26. Kong XD, Xu D, Zhang W, et al. Clinical features and prognosis in adult-onset Still’s disease: a study of 104 cases. Clin Rheumatol. 2010;29:1015–9.

    Article  PubMed  Google Scholar 

  27. Colina M, Zucchini W, Ciancio G, et al. The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum. 2011;41:279–85.

    Article  PubMed  Google Scholar 

  28. Chen PD, Yu SL, Chen S, Weng XH. Retrospective study of 61 patients with adult-onset Still’s disease admitted with fever of unknown origin in China. Clin Rheumatol. 2012;31:175–81.

    Article  PubMed  Google Scholar 

  29. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–9.

    Article  CAS  Google Scholar 

  30. Mehrpoor G, Owlia MB, Soleimani H, Ayatollahi J. Adult-onset Still’s disease: a report of 28 cases and review of the literature. Mod Rheumatol. 2008;18:480–5.

    Article  PubMed  Google Scholar 

  31. Ohira H, Abe K, Takahashi A. Involvement of the liver in rheumatic disease. Clin J Gastroenterol. 2012;5:9–14.

    Article  PubMed  Google Scholar 

  32. Ravelli A, Minoia F, Davì S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol. 2016;68:566–76.

    Article  PubMed  Google Scholar 

  33. Aida S. Alkaline phosphatase isoenzyme activities in rheumatoid arthritis: hepatobiliary enzyme dissociation and relation to disease activity. Ann Rheum Dis. 1993;52:511–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Matsumoto T, Kobayashi S, Shimizu H, et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000;20:366–73.

    Article  CAS  PubMed  Google Scholar 

  35. Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis. 2004;63:123–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Grover S, Rastogi A, Singh J, Rajbongshi A, Bihari C. Spectrum of histomorphologic findings in liver in patients with SLE: a review. Hepat Res Treat. 2014;2014:562979.

    PubMed Central  PubMed  Google Scholar 

  37. Bae CB, Jung JY, Kim HA, Suh CH. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients. Medicine (Baltimore). 2015;94:e451.

    Article  Google Scholar 

  38. Monoe K, Kanno Y, Saito H, et al. A case of hepatocellular carcinoma associated with mixed connective tissue disease. Nihon Shokakibyo Gakkai Zasshi. 2007;104:568–72.

    PubMed  Google Scholar 

  39. Karhunen PJ. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol. 1986;39:183–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Berzigotti A, Frigato M, Manfredini E, et al. Liver hemangioma and vascular liver diseases in patients with systemic lupus erythematosus. World J Gastroenterol. 2011;17:4503–8.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Folomeev M, Dougados M, Beaune J, Kouyoumdjian JC, Nahoul K, Amor B, et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus. 1992;1:191–5.

    Article  CAS  PubMed  Google Scholar 

  42. Robak E, Woźniacka A, Sysa-Jedrzejowska A, Stepień H, Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cytokine Netw. 2001;12:445–52.

    CAS  PubMed  Google Scholar 

  43. Robak E, Woźniacka A, Sysa-Jedrzejowska A, Stepień H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus. 2002;11:348–55.

    Article  CAS  PubMed  Google Scholar 

  44. Bichile T, Petri M. Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies. Curr Opin Rheumatol. 2014;26:111–7.

    Article  CAS  PubMed  Google Scholar 

  45. Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective. Mod Rheumatol. 2018;28:1–8.

    Article  CAS  PubMed  Google Scholar 

  46. Nocturne G, Mariette X. Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol. 2015;168:317–27.

    Article  CAS  PubMed  Google Scholar 

  47. Noronha V, Shafi NQ, Obando JA, Kummar S. Primary non-Hodgkin’s lymphoma of the liver. Crit Rev Oncol Hematol. 2005;53:199–207.

    Article  PubMed  Google Scholar 

  48. Page RD, Romaguera JE, Osborne B, et al. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer. 2001;92:2023–9.

    Article  CAS  PubMed  Google Scholar 

  49. Avlonitis VS, Linos D. Primary hepatic lymphoma: a review. Eur J Surg. 1999;165:725–9.

    Article  CAS  PubMed  Google Scholar 

  50. Yoshida Y, Takahashi Y, Yamashita H, et al. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. Mod Rheumatol. 2014;24:763–5.

    Article  CAS  PubMed  Google Scholar 

  51. Tatsumi G, Ukyo N, Hirata H, Tsudo M. Primary hepatic lymphoma in a patient with rheumatoid arthritis treated with methotrexate. Case Rep Hematol. 2014;2014:460574.

    PubMed Central  PubMed  Google Scholar 

  52. Kikuma K, Watanabe J, Oshiro Y, et al. Etiological factors in primary hepatic B-cell lymphoma. Virchows Arch. 2012;460:379–87.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Takasumi M, Okai K, Asano T, et al. A case of methotrexate-associated lymphoproliferative disorder diagnosed by liver biopsy. Nihon Shokakibyo Gakkai Zasshi. 2015;112:115–22.

    PubMed  Google Scholar 

  54. Alanazi T, Alqahtani M, Al Duraihim H, et al. Hepatic vasculitis mimicking liver abscesses in a patient with systemic lupus erythematosus. Ann Saudi Med. 2009;29:474–7.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Gibson T, Myers AR. Subclinical liver disease in systemic lupus erythematosus. J Rheumatol. 1981;8:752–9.

    CAS  PubMed  Google Scholar 

  56. Mukai M, Bohgaki T, Notoya A, et al. Liver dysfunction due to apoptosis in a patient with systemic lupus erythematosus. Lupus. 2000;9:74–7.

    Article  CAS  PubMed  Google Scholar 

  57. Liu Y, Yu J, Oaks Z, et al. Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus. Clin Immunol. 2015;160:319–27.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Ambrosino P, Lupoli R, Spadarella G, et al. Autoimmune liver diseases and antiphospholipid antibodies positivity: a meta-analysis of literature studies. J Gastrointestin Liver Dis. 2015;24:25–34, 3 p following 34.

    PubMed  Google Scholar 

  59. Oaks Z, Winans T, Caza T, et al. Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to rapamycin in lupus-prone mice. Arthritis Rheumatol. 2016;68:2728–39.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Fang X, Zaman MH, Guo X, et al. Role of hepatic deposited immunoglobulin G in the pathogenesis of liver damage in systemic lupus erythematosus. Front Immunol. 2018;9:1457.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Abe K, Takahashi A, Nozawa Y, et al. The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases. Med Mol Morphol. 2014;47:162–8.

    Article  CAS  PubMed  Google Scholar 

  62. Thompson PW, Houghton BJ, Clifford C, et al. The source and significance of raised serum enzymes in rheumatoid arthritis. Q J Med. 1990;76:869–79.

    CAS  PubMed  Google Scholar 

  63. Malnick S, Melzer E, Sokolowski N, Basevitz A. The involvement of the liver in systemic diseases. J Clin Gastroenterol. 2008;42:69–80.

    Article  PubMed  Google Scholar 

  64. Tojo J, Ohira H, Abe K, et al. Autoimmune hepatitis accompanied by systemic lupus erythematosus. Intern Med. 2004;43:258–62.

    Article  PubMed  Google Scholar 

  65. Ohira H, Takiguchi J, Rai T, et al. High frequency of anti-ribosomal P antibody in patients with systemic lupus erythematosus-associated hepatitis. Hepatol Res. 2004;28:137–9.

    Article  CAS  PubMed  Google Scholar 

  66. Takahashi A, Arinaga-Hino T, Ohira H, et al. Autoimmune hepatitis in Japan: trends in a nationwide survey. J Gastroenterol. 2017;52:631–40.

    Article  CAS  PubMed  Google Scholar 

  67. Abe M, Mashiba T, Zeniya M, et al. Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011;46:1136–41.

    Article  CAS  PubMed  Google Scholar 

  68. Oka H. The survey of autoimmune hepatitis in Japan. Annual Report of the Study Group on Severe Hepatitis. Japanese Ministry of Health and Welfare. 1988;235–41. (Japanese).

    Google Scholar 

  69. Teufel A, Weinmann A, Kahaly GJ, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010;44:208–13.

    Article  CAS  PubMed  Google Scholar 

  70. Iwai M, Harada Y, Ishii M, et al. Autoimmune hepatitis in a patient with systemic lupus erythematosus. Clin Rheumatol. 2003;22:234–6.

    Article  CAS  PubMed  Google Scholar 

  71. Quintin E, Scoazec JY, Marotte H, Miossec P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther. 2010;12:R143.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Toulemonde G, Scoazec JY, Miossec P. Treatment with etanercept of autoimmune hepatitis associated with rheumatoid arthritis: an open label proof of concept study. Ann Rheum Dis. 2012;71:1423–4.

    Article  CAS  PubMed  Google Scholar 

  73. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9:188–93.

    Article  CAS  PubMed  Google Scholar 

  74. Rodrigues S, Lopes S, Magro F, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. World J Gastroenterol. 2015;21:7584–8.

    Article  PubMed Central  PubMed  Google Scholar 

  75. Ramos-Casals M, Sánchez-Tapias JM, Parés A, et al. Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren’s syndrome. J Rheumatol. 2006;33:1593–9.

    PubMed  Google Scholar 

  76. Karp JK, Akpek EK, Anders RA. Autoimmune hepatitis in patients with primary Sjögren’s syndrome: a series of two-hundred and two patients. Int J Clin Exp Pathol. 2010;3:582–6.

    PubMed Central  PubMed  Google Scholar 

  77. Fragoulis GE, Skopouli FN, Selmi C, Gershwin ME. Liver involvement in primary Sjögren’s syndrome. In: Ramos-Casals M, Stone J, Moutsopoulos H, editors. Sjögren’s syndrome. Diagnosis and therapeutics. London: Springer; 2012. p. 237–46.

    Google Scholar 

  78. Efe C, Wahlin S, Ozaslan E, et al. Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol. 2012;24:531–4.

    Article  PubMed  Google Scholar 

  79. Matsumoto T, Morizane T, Aoki Y, et al. Autoimmune hepatitis in primary Sjogren’s syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren’s syndrome. Pathol Int. 2005;55:70–6.

    Article  PubMed  Google Scholar 

  80. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–73.

    Article  CAS  PubMed  Google Scholar 

  81. Hirohara J. National surveys of primary biliary cirrhosis (PBC) in Japan. Annual Report of the intractable Liver and Biliary Diseases Study Group of Japan. Japanese Ministry of Health, Labour and Welfare. 2016;59–65. (Japanese). https://mhlw-grants.niph.go.jp.

  82. De Santis M, Crotti C, Selmi C. Liver abnormalities in connective tissue diseases. Best Pract Res Clin Gastroenterol. 2013;27:543–51.

    Article  PubMed  Google Scholar 

  83. Wang L, Zhang FC, Chen H, et al. Connective tissue diseases in primary biliary cirrhosis: a population-based cohort study. World J Gastroenterol. 2013;19:5131–7.

    Article  PubMed Central  PubMed  Google Scholar 

  84. Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM. 2004;97:397–406.

    Article  CAS  PubMed  Google Scholar 

  85. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42:1194–202.

    Article  PubMed  Google Scholar 

  86. Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis. 2001;60:1046–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  87. Hatzis GS, Fragoulis GE, Karatzaferis A, et al. Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren’s syndrome. J Rheumatol. 2008;35:2012–6.

    PubMed  Google Scholar 

  88. Zeron PB, Retamozo S, Bové A, et al. Diagnosis of liver involvement in primary Sjögren syndrome. J Clin Transl Hepatol. 2013;1:94–102.

    PubMed Central  PubMed  Google Scholar 

  89. Assassi S, Fritzler MJ, Arnett FC, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol. 2009;36:2250–6.

    Article  PubMed Central  PubMed  Google Scholar 

  90. Hansen BU, Eriksson S, Lindgren S. High prevalence of autoimmune liver disease in patients with multiple nuclear dot, anti-centromere, and mitotic spindle antibodies. Scand J Gastroenterol. 1991;26:707–13.

    Article  CAS  PubMed  Google Scholar 

  91. Shoji I, Takagi T, Kasukawa R. Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern Med. 1992;31:1348–55.

    Article  CAS  PubMed  Google Scholar 

  92. Rigamonti C, Shand LM, Feudjo M, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut. 2006;55:388–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  93. Tojo J, Ohira H, Suzuki T, et al. Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. Hepatol Res. 2002;22:187–95.

    Article  PubMed  Google Scholar 

  94. Saito H, Takahashi A, Abe K, et al. Two cases of primary biliary cirrhosis associated with systemic lupus erythematosus. Kanzo. 2011;52:169–75.

    Article  Google Scholar 

  95. Picceli VF, Skare TL, Nisihara R, et al. Spectrum of autoantibodies for gastrointestinal autoimmune diseases in systemic lupus erythematosus patients. Lupus. 2013;22:1150–5.

    Article  CAS  PubMed  Google Scholar 

  96. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–7.

    Article  CAS  PubMed  Google Scholar 

  97. Shizuma T, Kuroda H. A case of primary biliary cirrhosis which developed eight years after diagnosis of systemic lupus erythematosus. Intern Med. 2011;50:321–4.

    Article  PubMed  Google Scholar 

  98. Hammami S, Chaabane N, Mahmoudi H, Bdioui F, Saffar H. Late-onset systemic lupus erythematosus-associated primary biliary cirrhosis. Int Arch Med. 2013;6:3.

    Article  PubMed Central  PubMed  Google Scholar 

  99. Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010;42:658–60.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  100. Radovanović-Dinić B, Tešić-Rajković S, Zivkovic V, Grgov S. Clinical connection between rheumatoid arthritis and liver damage. Rheumatol Int. 2018;38:715–24.

    Article  PubMed  Google Scholar 

  101. Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta. 2011;412:502–12.

    Article  CAS  PubMed  Google Scholar 

  102. Datta A, Deodhar SD, Datta U, Sehgal S. Non-organ specific & organ specific antibodies in rheumatoid arthritis. Indian J Med Res. 1990;92:228–32.

    CAS  PubMed  Google Scholar 

  103. Zurgil N, Bakimer R, Moutsopoulos HM, et al. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol. 1992;12:201–9.

    Article  CAS  PubMed  Google Scholar 

  104. Mouritsen S, Demant E, Permin H, Wiik A. High prevalence of anti-mitochondrial antibodies among patients with some well-defined connective tissue diseases. Clin Exp Immunol. 1986;66:68–76.

    CAS  PubMed Central  PubMed  Google Scholar 

  105. Liaskos C, Bogdanos DP, Rigopoulou EI, Dalekos GN. Development of antimitochondrial antibodies in patients with autoimmune hepatitis: art of facts or an artifact? J Gastroenterol Hepatol. 2007;22:454–5.

    Article  PubMed  Google Scholar 

  106. Smyk DS, Bogdanos DP, Mytilinaiou MG, Burroughs AK, Rigopoulou EI. Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? Arthritis. 2012;2012:391567.

    Article  PubMed Central  PubMed  Google Scholar 

  107. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150:1599–608.

    Article  PubMed  Google Scholar 

  108. Brito-Zerón P, Gheitasi H, Retamozo S, et al. How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients. Arthritis Res Ther. 2015;17:250.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  109. Toussirot E, Le Huédé G, Mougin C, Balblanc JC, Bettinger D, Wendling D. Presence of hepatitis C virus RNA in the salivary glands of patients with Sjögren’s syndrome and hepatitis C virus infection. J Rheumatol. 2002;29:2382–5.

    CAS  PubMed  Google Scholar 

  110. Koike K, Moriya K, Ishibashi K, et al. Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci U S A. 1997;94:233–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  111. Patel R, Mikuls TR, Richards JS, et al. Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection. Arthritis Care Res (Hoboken). 2015;67:467–74.

    Article  CAS  Google Scholar 

  112. Morito T, Nishimagi T, Onizawa N, et al. Studies on complement of sera with liver diseases. Kanzo. 1977;45:925–35.

    Article  Google Scholar 

  113. Cacoub P, Commarmond C, Sadoun D, Desbois AC. Hepatitis C virus infection and rheumatic diseases: the impact of direct-acting antiviral agents. Rheum Dis Clin North Am. 2017;43:123–32.

    Article  PubMed  Google Scholar 

  114. Lee YH, Ji JD, Yeon JE, et al. Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection. Ann Rheum Dis. 1998;57:728–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  115. Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75:1777–82.

    Article  CAS  PubMed  Google Scholar 

  116. Sise ME, Bloom AK, Wisocky J, Lin MV, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408–17.

    Article  CAS  PubMed  Google Scholar 

  117. Watanabe R, Ishii T, Kobayashi H, et al. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey. Tohoku J Exp Med. 2014;233:129–33.

    Article  PubMed  Google Scholar 

  118. Tsai WP, Chen MH, Lee MH, et al. Cytomegalovirus infection causes morbidity and mortality in patients with autoimmune diseases, particularly systemic lupus: in a Chinese population in Taiwan. Rheumatol Int. 2012;32:2901–8.

    Article  CAS  PubMed  Google Scholar 

  119. Zhang J, Dou Y, Zhong Z, et al. Clinical characteristics and therapy exploration of active human cytomegalovirus infection in 105 lupus patients. Lupus. 2014;23:889–97.

    Article  CAS  PubMed  Google Scholar 

  120. Komura T, Ohta H, Nakai R, et al. Cytomegalovirus reactivation induced acute hepatitis and gastric erosions in a patient with rheumatoid arthritis under treatment with an anti-IL-6 receptor antibody, tocilizumab. Intern Med. 2016;55:1923–297.

    Article  PubMed  Google Scholar 

  121. Bauer H, Luxembourger C, Gottenberg JE, et al. Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study. Medicine (Baltimore). 2015;94:e675.

    Article  CAS  Google Scholar 

  122. Sugawara N, Yawata A, Takahashi K, Abe N, Arai M. The third case of fulminant hepatitis associated with “Kitami/Abashiri train” of hepatitis E virus genotype 4. Kanzo. 2009;50:473–4.

    Article  Google Scholar 

  123. Horizon AA, Wallace DJ. Risk: benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf. 2004;3:273–8.

    Article  CAS  PubMed  Google Scholar 

  124. Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol. 2010;16:5651–61.

    Article  PubMed Central  PubMed  Google Scholar 

  125. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011;127:303–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  126. Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014;23:225–35.

    Article  CAS  PubMed  Google Scholar 

  127. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26:1275–9.

    CAS  PubMed  Google Scholar 

  128. Visser K, van der Heijde DM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol. 2009;27:1017–25.

    CAS  PubMed  Google Scholar 

  129. Sakthiswary R, Chan GY, Koh ET, Leong KP, Thong BY. Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. Sci World J. 2014;2014:823763.

    Article  CAS  Google Scholar 

  130. Hakim NS, Kobienia B, Benedetti E, Bloomer J, Payne WD. Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. Int Surg. 1998;83:224–5.

    CAS  PubMed  Google Scholar 

  131. Mori S, Arima N, Ito M, et al. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One. 2018;13:e0203084.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  132. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.

    Article  CAS  PubMed  Google Scholar 

  133. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710–23.

    Article  CAS  PubMed  Google Scholar 

  134. Miyata M, Kuroda M, Unakami M, et al. Validation of the Fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate. Mod Rheumatol. 2018;31:1–20. https://doi.org/10.1080/14397595.2018.1542962.

    Article  CAS  Google Scholar 

  135. Deane S, Selmi C, Teuber SS, Gershwin ME. Macrophage activation syndrome in autoimmune disease. Int Arch Allergy Immunol. 2010;153:109–20.

    Article  CAS  PubMed  Google Scholar 

  136. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139:713–27.

    Article  CAS  PubMed  Google Scholar 

  137. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985;106:561–6.

    Article  CAS  PubMed  Google Scholar 

  138. Ravelli A, Minoia F, Davì S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis. 2016;75:481–9.

    Article  CAS  PubMed  Google Scholar 

  139. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.

    Article  PubMed  Google Scholar 

  140. Wong KF, Hui PK, Chan JK, Chan YW, Ha SY. The acute lupus hemophagocytic syndrome. Ann Intern Med. 1991;114:387–90.

    Article  CAS  PubMed  Google Scholar 

  141. Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003;49:633–9.

    Article  PubMed  Google Scholar 

  142. Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev. 2004;3:69–75.

    Article  CAS  PubMed  Google Scholar 

  143. Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol. 2014;66:2297–307.

    Article  PubMed Central  PubMed  Google Scholar 

  144. Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14:194.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Atsushi Takahashi & Hiromasa Ohira

Authors
  1. Atsushi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiromasa Ohira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atsushi Takahashi .

Editor information

Editors and Affiliations

  1. Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Hiromasa Ohira

  2. Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Kiyoshi Migita

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Takahashi, A., Ohira, H. (2019). Liver Involvement in Rheumatic Diseases. In: Ohira, H., Migita, K. (eds) Gastrointestinal and Hepatic Manifestations of Rheumatic Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-13-6524-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-6524-9_1

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-6523-2

  • Online ISBN: 978-981-13-6524-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation